AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21806906
Drug: Freeze dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried powdered combination of Lactobacillus rhamnosus and Bifidobacterium species
Trial: 21806906
Drug: Freeze dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried powdered preparation of Bacillus coagulans
Trial: 11336156
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. over 5 days
Trial: 9160036
Drug: Brow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brow treatment (B)
Trial: 9160036
Drug: Inner orbital
RxNorm normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inner orbital treatment (IO)
Trial: 9160036
Drug: Outer orbital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer orbital treatment (OO)
Trial: 31373696
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered glucocorticosteroids preoperatively
Trial: 31373696
Drug: Endoscopic sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sinus surgery (ESS) without preoperative steroids
Trial: 31217344
Drug: Palbociclib +
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib + letrozole (palbociclib: 125 mg daily; 3 weeks on/1 week off; letrozole: 2.5 mg daily continuously)
Trial: 31217344
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + letrozole (letrozole: 2.5 mg daily continuously)
Trial: 14704262
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (0.05 mg/d) plus progestin (2.5 mg/d; n = 31)
Trial: 14704262
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (0.625 mg/d) plus progestin (2.5 mg/d; n = 30)
Trial: 9220037
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core (CC)
Trial: 29234884
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy combined with steroid injection (Group 1)
Trial: 29234884
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (Group 2)
Trial: 26909885
Drug: Gaviscon Advance
RxNorm normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon Advance 10 mL four times a day
Trial: 24982236
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with DFX 30 mg/kg
Trial: 24982236
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with DFP 80 mg/kg/day
Trial: 24982236
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with DFX 30 mg/kg and DFP 40 mg/kg
Trial: 24982236
Drug: Concurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent therapy with DFX 30 mg/kg and DFP 80 mg/kg
Trial: 22156009
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection (C: 6 mL/s; D: 8 mL/s)
Trial: 22156009
Drug: Unilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral injection (A: 4 mL/s; B: 6 mL/s)
Trial: 20728299
Drug: B-MAT (buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-MAT (buprenorphine medication-assisted treatment)
Trial: 19167585
Drug: Prefilled insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prefilled insulin delivery device (NovoMix 30 FlexPen)
Trial: 19167585
Drug: Reusable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reusable insulin delivery device (HumaPen Luxura)
Trial: 19167585
Drug: Injection time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection time excluding cartridge insertion for HL device
Trial: 11174477
Drug: Estradiol plus
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol plus sequential norethindrone acetate
Trial: 30957447
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (surround needling + acupoint injection)
Trial: 28416501
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU, twice daily for 2 weeks)
Trial: 28416501
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 2 weeks)
Trial: 22972566
Drug: Ketofol (1:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketofol (1:1 mixture of 5 mg/ml ketamine and 5 mg/ml propofol)
Trial: 22972566
Drug: Propofol 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.15 ml/kg
Trial: 12949687
Drug: Epigam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigam (1 tablet, 6 times a day)
Trial: 12949687
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg, 2 times a day)
Trial: 9055055
Drug: Slow-release gemfibrozil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release gemfibrozil, 1200 mg once daily
Trial: 25236993
Drug: Desmopressin orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin orally disintegrating tablet
Trial: 16988138
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk (FM) with 5.8 mg iron as ferrous gluconate, 5.28 mg zinc as zinc oxide, and 48 mg ascorbic acid per 400 mL
Trial: 16988138
Drug: Nonfortified milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfortified milk (NFM) with 0.2 mg iron, 1.9 mg zinc, and 6.8 mg ascorbic acid per 400 mL
Trial: 12729425
Drug: 10-mg warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg warfarin initiation nomogram
Trial: 12729425
Drug: 5-mg warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg warfarin initiation nomogram
Trial: 10979111
Drug: Celecoxib, 400
RxNorm normalized name: Celecoxib, 400 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib, 400 mg twice per day (n = 3987)
Trial: 10979111
Drug: NSAIDs (ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen, 800 mg 3 times per day; n = 1985) or diclofenac, 75 mg twice per day (n = 1996)
Trial: 29943384
Drug: Herbal vaginal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil, prescribed for 3 months (20 suppositories at each menstrual cycle)
Trial: 29943384
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository, prescribed for 3 months (20 suppositories at each menstrual cycle)
Trial: 29943384
Drug: Herbal vaginal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil
Trial: 26873229
Drug: Daclizumab HYP
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab HYP (150 mg SC every 4 weeks)
Trial: 26873229
Drug: Daclizumab HYP
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab HYP (100-300 mg SC)
Trial: 12195876
Drug: Lamivudine and
RxNorm normalized name: lamivudine and abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine and famciclovir combination therapy
Trial: 12195876
Drug: Lamivudine and
RxNorm normalized name: lamivudine and abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine and famciclovir combination therapy with IFN-alpha 2b
Trial: 10096821
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite avoidance therapy (including allergen-impermeable encasement of mattresses and other strategies)
Trial: 7534055
Drug: Control (non-heparin-coated)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (non-heparin-coated) cardiopulmonary bypass
Trial: 678387
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg long‐acting capsule formulation (LA)
Trial: 678387
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg twice a day regimen (CP80)
Trial: 30309970
Drug: Sequential DMARD-monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential DMARD-monotherapy (sulfasalazine or methotrexate)
Trial: 30309970
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy MTX + 6 weeks prednisolone
Trial: 30309970
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy MTX + etanercept
Trial: 25710801
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate (SC) 1600 mg, three times a day
Trial: 21849147
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Mailuo Shutong Granule + Hirudoid cream)
Trial: 19433997
Drug: Team care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team care with proactive clinical pharmacist services (medication history, patient-care round participation, resolution of drug-related issues, discharge counseling)
Trial: 14616458
Drug: oxybutynin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxybutynin IR 3 mg three times daily
Trial: 1359166
Drug: Timing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing with priming (0.005 mg.kg‐1 vecuronium as priming doses followed by 0.15 mg.kg‐1 vecuronium)
Trial: 1359166
Drug: Timing (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing (0.15 mg.kg‐1 vecuronium)
Trial: 30184110
Drug: JNJ‐9375 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐9375 (250 μg/mL)
Trial: 30184110
Drug: JNJ‐9375 (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐9375 (2.5, 25, and 250 μg/mL)
Trial: 30184110
Drug: Bivalirudin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (6 μg/mL)
Trial: 21787883
Drug: Ovulation induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation induction (OI) with aromatase inhibitor
Trial: 19340902
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of oral allopurinol at 15 h and 3 h before ERCP
Trial: 19340902
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo at the same times as the allopurinol group
Trial: 15103755
Drug: Serum concentration
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum concentration of prolactin before treatment in hyperprolactinemic patients
Trial: 9146905
Drug: Sugar alcohols
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar alcohols (polyols) in aqueous solutions
Trial: 7712903
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + misoprostol 600 micrograms (Group 1)
Trial: 7712903
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + PG05 1 mg vaginal suppository (Group 2)
Trial: 24200748
Drug: Losartan (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50mg daily for 4 weeks)
Trial: 24200748
Drug: Trichlormethiazide (4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichlormethiazide (4mg daily for 4 weeks)
Trial: 23332861
Drug: FF 200
RxNorm normalized name: guaifen/pe/acetaminophen/caff 200 mg-10 mg-325 mg-32.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF 200 μg
Trial: 21715530
Drug: Duloxetine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (120 mg)
Trial: 19228745
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine alone (arm A)
Trial: 19228745
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine + GM-CSF (arm B)
Trial: 19228745
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine + IFN-alpha2b (arm C)
Trial: 19228745
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine + IFN-alpha2b + GM-CSF (arm D)
Trial: 19228745
Drug: Vaccine immune
RxNorm normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine immune response
Trial: 10684783
Drug: Alcohol (0.34,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.34, 0.68, and 1.02 g/kg)
Trial: 8364943
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 0.075% cream
Trial: 8364943
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 0.075% cream (long-term phase)
Trial: 29897249
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg once-daily)
Trial: 29897249
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide alone
Trial: 24495204
Drug: Couples treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples treatment
Trial: 24495204
Drug: Individuals treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals treatment
Trial: 23539727
Drug: Levothyroxine (L-T₄)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T₄)
Trial: 16192761
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 (8 mg/kg)
Trial: 16192761
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 (0.1-8.0 mg/kg)
Trial: 12905476
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg every 6 weeks after induction phase)
Trial: 7892316
Drug: Rapid expansion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid expansion starting 1 week postoperatively on a daily basis; expansion period of 14 days.
Trial: 29779802
Drug: Trophic feeds
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trophic feeds (10‐20 ml/kg/day) starting 4‐6 hours after surgery
Trial: 21749488
Drug: Supplement containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement containing 10 mg of ferrous sulphate
Trial: 15777442
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulphate 80 mg daily
Trial: 7547822
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of 100 g/l Intralipid (8.36 kJ/min)
Trial: 7547822
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (9 g NaCl/l)
Trial: 2389909
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 0.2 mg inhaled three times a day for 2 months
Trial: 2389909
Drug: Placebo inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled three times a day for 2 months
Trial: 2389909
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) treatment withheld after second antigen provocation
Trial: 25590523
Drug: sTM levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTM levels at enrollment (highest quartile > 14 ng/mL vs. lowest quartile < 7 ng/mL)
Trial: 25590523
Drug: Syndecan‐1 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndecan‐1 levels at enrollment (> 240 vs. < 70 ng/mL)
Trial: 24024727
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (ropinirole 0.25 mg/d)
Trial: 21338496
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechins (378 mg/day) and theanine (210 mg/day)
Trial: 8040671
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with cisplatin and fluorouracil (5‐FU) followed by radiation therapy
Trial: 8040671
Drug: Standard surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgery followed by radiation therapy
Trial: 4880259
Drug: Hypnosis (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (monthly sessions and daily autohypnosis for one year)
Trial: 28000127
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure-lowering treatment (target SBP <140 mmHg within 1 hour)
Trial: 28000127
Drug: Guideline-recommended blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended blood pressure-lowering treatment (target SBP <180 mmHg)
Trial: 26362235
Drug: Corticosteroid (Steroid)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (Steroid) injection
Trial: 18280832
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy measures (feeding modifications, positioning, tobacco smoke avoidance)
Trial: 16556888
Drug: Consolidation/maintenance chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation/maintenance chemotherapy
Trial: 11194431
Drug: Ropivacaine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (200 mg)
Trial: 8791948
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d.
Trial: 8791948
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d. plus Clarithromycin 250 mg b.d.
Trial: 1620416
Drug: Intravenous phosphocreatine
RxNorm normalized name: phosphocysteamine
DrugBank: Phosphocysteamine (DB17640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phosphocreatine administered after induction of anaesthesia, prior to cardiac arrest and after release of aortic cross-clamp
Trial: 1620416
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group A)
Trial: 28831717
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment (until hospital discharge)
Trial: 25934015
Drug: External counterpulsation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External counterpulsation (ECP) treatment, 35 daily 1 hour sessions
Trial: 21880037
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Trial: 21880037
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil (SO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Trial: 21880037
Drug: Saline, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Trial: 9809934
Drug: Myocardial contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocardial contrast echocardiography (MCE) using bolus doses of a perfluorocarbon‐filled contrast agent (NC100100)